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Introduction
Benign prostate hyperplasia (BPH) is one of 
the diseases often discovered in men aged 
70–79 years by 80%.1,2 In the course of the 
disease, BPH will become benign prostatic 
enlargement (BPE) that obstructs the lower 
urinary tract.3,4 This obstruction causes lower 
urinary tract symptoms (LUTS) and about 
25–50% of individuals with BPH experience 
LUTS.3,5
One of the complications of BPH is urinary 
tract stones, especially bladder stones.5 Benign 
prostatic hyperplasia is not the only risk 
factor related to the occurrence of urinary 
tract stones, but there are also intrinsic and 
extrinsic factors.6 The intrinsic factors consist 
of age, sex, race, heredity, metabolic disorders, 
systemic diseases, urinary tract infections, 
and anatomic abnormalities of the urinary 
tract, whereas the extrinsic factors consist of 
patterns of nutrition, climate, occupation, and 
education level.6,7
The symptoms of lower urinary tract 
stones in patients with BPH can be masked 
by symptoms of the BPH. The most frequent 
symptoms are hematuria (37.1%) and urinary 
disorders (32.5%). About 2.6% of patients with 
bladder stones have experienced symptoms 
of acute urinary retention that are probably 
caused by BPH or the stones themselves. 
Lower urinary tract stones in patients with 
BPH often go undetected because 15.5% 
are asymptomatic and are only found on 
routine examinations.5 Imaging tests are not 
carried out regularly on patients with BPH in 
Indonesia.8 Imaging tests are only provided if 
the patients have hematuria, recurrent urinary 
tract infections, renal insufficiency, excessive 
urine residues, history of stones, and history 
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Abstract
Background: Urinary tract stones are common in patients with benign prostatic hyperplasia (BPH); 
therefore, an imaging test is needed for patients who have risk factors for the formation of urinary 
tract stones. The purpose of this study was to explore the factors associated with the presence of 
urinary tract stones in patients with BPH as information to conduct imaging tests.
Methods: A cross-sectional quantitative analytic study was conducted on medical records of patients 
with BPH, both with and without urinary tract stones, or patients with urinary tract stones registered 
at the Department of Urology, Dr. Hasan Sadikin General Hospital, Indonesia, from 2015 to 2018. 
Data on age, body mass index, hypertension, use of antihypertensive drugs, diabetes mellitus, and 
hyperuricemia were collected and analyzed using the Mann-Whitney, Chi-square, Fisher exact test, 
and multivariate logistic regression statistical test to compare variables between BPH with and 
without urinary tract stones.
Results: In total, 235 BPH patients were registered, of whom 74 (31.5%) had urinary tract stones. 
The median age was 64 years old. There was a relationship between age (p=0.030), diabetes mellitus 
(p=0.043), and the occurrence of urinary tract stones in patients with BPH. The most dominant risk 
factor was diabetes mellitus (OR=3.000, 95%CI 1.03-8.69).
Conclusions: Age and diabetes mellitus are the risk factors for urinary tract stones in patients with 
BPH. BPH patients with diabetes mellitus are at a 3-fold risk for urinary tract stones. Diabetes mellitus 
in BPH patients is an indication to conduct imaging tests.
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of surgery on the urinary tract,8 leading to 
undiagnosed urinary tract stones. Therefore, 
the purpose of this study was to analyze 
other risk factors related to the presence of 
urinary tract stones in BPH patients as extra 
information to conduct the imaging tests.
Methods
A cross-sectional analytical study was carried 
out using secondary data from registries and 
medical records of patients with BPH with or 
without urinary tract stones in the Department 
of Urology Dr. Hasan Sadikin General Hospital 
Bandung, West Java, Indonesia. These patients 
were registered at the hospital from 2015 
to 2018. This study was approved by the 
Research Ethics Committee of Universitas 
Padjadjaran Bandung number 749/UN6.KEP/
EC/2019. The BPH patients were grouped 
into group 1 that had BPH without urinary 
tract stones, and group 2 that had BPH with 
urinary tract stones. The inclusion criteria in 
this study were registries and medical records 
of BPH and urinary tract stones with BPH 
patients which contained data of age, blood 
pressure, body mass index (BMI), diabetes 
status, hyperuricemia status, and the use of 
antihypertensive drugs. Double registries/
medical records of the same patients were 
excluded. Age was divided into ≤59 years, 60–
69 years, and ≥70 years. Blood pressure was 
divided into no hypertension when systolic 
blood pressure was ≤139 mmHg or diastolic 
blood pressure ≤89 mmHg or the history of 
hypertension was not recorded, and having 
hypertension when systolic blood pressure 
≥140 mmHg or diastolic blood pressure ≥90 
mmHg or there was a history of hypertension.9 
No obesity was designated when BMI <23 
kg/m2, and obesity if BMI ≥23 kg/m2.10 No 
diabetes mellitus (DM) was designated when 
fasting blood sugar level was <126 mg/dl and 
DM when fasting blood sugar level was ≥126 
mg/dl. Not hyperuricemia when blood uric 
acid level was ≤6.8 mg/dl and hyperuricemia 
when blood uric acid level was >6.8 mg/dl. The 
use of antihypertensive drugs was recorded as 
using and not using antihypertensive drugs.
To test the distribution of the numerical 
data, the Kolmogorov-Smirnov test was carried 
out and when the result was not normally 
distributed, the bivariate statistical test used 
in this study was the non-parametric Mann-
Whitney test. The Chi-square statistical test 
was used for analyzing hypertension, obesity, 
and the use of antihypertensive drugs while 
Fisher’s exact test was used for analyzing 
the DM and hyperuricemia data. The logistic 
regression statistical test was used to analyze 
the most dominant factor for the occurrence of 
urinary tract stones in patients with BPH. The 
statistical analyses was performed using IBM 
SPSS Statistics Software, Version 25.0.
Results
In total, data on 235 patients with BPH were 
retrieved, of which 31.5% had urinary tract 
stones (Table 1). Moreover, most locations of 
urinary tract stones were in the lower urinary 
tract (47.3%). Interestingly, the location of the 
stones would be both upper and lower urinary 
tract stones (32.4%). 
The median age of BPH patients was 68 
years old, whereas the median age of BPH 
patients with urinary tract stones was 64 
years old. The results showed that there was 
a relationship between age and the occurrence 
of urinary tract stones in BPH patients 
(p=0.030). The BPH with urinary tract was 
mostly affected in patients aged 60–69 years 
(58.1%). The increasing age was a risk for 
urinary tract stones in BPH patients (p=0.004).







BPH with urinary tract stones :
     Upper urinary tract stones
     Lower urinary tract stones  










Note: BPH= Benign prostatic hyperplasia
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There were 5 risk factors for urinary 
tract stones in BPH patients that were tested 
statistically, which were hypertension, obesity, 
diabetes mellitus, hyperuricemia, and the 
use of antihypertension drugs as shown in 
Table 5. This study showed that there was 
a similar percentage between hypertensive 
and normotensive BPH patients experiencing 
urinary tract stones (32.3% and 31.6%, 
respectively). The result showed that there 
was no relationship between hypertension 
and urinary tract stones in  BPH patients.
Obesity is one of the factors that 
contributed to the occurrence of urinary tract 
stones. This study had shown that 30.3% of 
obesity a patient with BPH had urinary tract 
stones. This percentage was lower compared 
to patients who were not obese. However, 
there was no relationship between obesity 
and the occurrence of urinary tract stones in 
BPH patients. Interestingly, the percentage of 
diabetes mellitus in BPH patients with urinary 
Table 3 Other Risk Factors for Urinary Tract Stones in BPH Patients 
Risk Factor
BPH Urinary Tract Stones in BPH Total p-value
(n=161) (n=74) (n=235)
Hypertension
     No hypertension
     Hypertension










     No obesity
     Obesity










     No diabetes mellitus
     Diabetes mellitus










     No hyperuricemia
     Hyperuricemia









The use of antihypertensive drugs
     Negative
     Positive









Notes: ** Chi-Square statistical test, *** Fisher’s Exact Test










     Median, years
     Minimum, years








     ≤59 years old (n, %)
     60–69 years old (n, %)











Notes: * Mann-Whitney statistical test, ** Chi-Square statistical test
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tract stones was 53.3%. This percentage was 
higher compared to patients without diabetes 
mellitus. There was a relationship between 
diabetes mellitus and urinary tract stones in 
BPH patients (p=0.043).
Hyperuricemia was found only in 16 of 
48 BPH patients. Of these, 12 BPH patients 
were found with urinary tract stones 
and there was no relationship between 
hyperuricemia with the occurrence of urinary 
tract stones in BPH patients. Furthermore, 
there was no relationship between the use of 
antihypertensive drugs with the occurrence of 
urinary tract stones in BPH patients.
Antihypertensive drugs were used by 
BPH patients who had hypertension or with 
a history of hypertension. The two most 
commonly antihypertensive drugs used were 
calcium-channel blockers and angiotensin-
converting enzyme inhibitors (Table 4).
The most dominant risk factor for the 
occurrence of urinary tract stones in BPH 
patients was diabetes mellitus. The BPH 
patients with diabetes mellitus had a 3-fold risk 
of developing urinary tract stones compared 
to BPH patients without diabetes mellitus 
(Odds Ratio=3.000; the Wald value was >3.84 
and p-value <0.05; CI 95% 1.039–8.695).
Discussions
Factors associated with the occurrence of 
urinary tract stones include age, race, heredity, 
metabolic syndrome, systemic disease, urinary 
tract infections, anatomical abnormalities of 
the urinary tract, nutritional patterns, climate, 
and occupation.4,6,7 Our study has shown that 
hypertension, obesity, hyperuricemia, and the 
use of antihypertension drugs are not related 
to the presence of urinary tract stones in 
BPH patients. Interestingly, age and diabetes 
mellitus are associated with the presence of 
urinary tract stones in BPH patients. 
Hypertension as a risk factor for urinary 
tract stones is still controversial. A systematic 
review and meta-analysis study have shown 
that hypertension significantly increases the 
excretion of calcium, oxalate, and uric acid 
in the urine, leading to stone formation.11 
Furthermore, the occurrence of hypertension 
can also be caused by the occurrence of kidney 
stones, so that there is a two-way relationship 
between the incidence of hypertension and 
urinary tract stones.12 However, a report 
from Germany13 revealed that there was no 
difference in the risk of kidney stones between 
patients with hypertension and patients who 
were not, similar to our study that shows 
no relationship between hypertension and 
urinary tract stones in BPH patients. This is 
probably because most hypertensive patients 
are currently under treatment.
The study has shown that obesity is 
associated with an increased risk of kidney 
stones,12 by excreting more calcium, oxalate, 
and uric acid in urine. Furthermore,  increased 
body mass index is associated with a 
significantly decreased urine pH.14,15 About 
63% of the stones in obese people contain uric 
acid stones.15 However, our result shows no 
relationship between obesity and the presence 
of urinary tract stones in BPH patients. This 
controversial result is probably caused by the 
small number of obese patients in this study, 
which is only 38.8% of BPH patients. 
The level of blood uric acid contributes 
to the formation of urinary tract stones. The 
higher levels of blood uric acid, the higher the 
risk of urinary tract stones.16 Hyperuricemia 
will reduce the pH in urine, which can cause 
uric acid stones.16 However, our result 
shows that there is no relationship between 
hyperuricemia with the presence of urinary 
tract stones in BPH patients. This study 
contradicts the previous studies, again it 
might be due to the small number of samples 
and many data were missing. In Indonesia, 
not all BPH patients are tested for blood 
Table 4 Antihypertension Drugs 
Antihypertension Drugs
BPH Urinary Tract Stones in BPH Total





















Notes: * one patient could consume more than one type of antihypertension drug
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uric acid levels routinely. A retrospective 
cohort study has shown that thiazide-type 
antihypertensive drugs can reduce the risk 
of urinary tract stone formation, by reducing 
calcium levels in the urine.17 On the contrary, 
another antihypertensive drug of angiotensin-
converting enzyme-inhibitor (ACEI) or 
angiotensin receptor blocker (ARB) and 
calcium channel blocker (CCB) can increase 
the level of calcium in the urine, thus it serves 
as a risk to the formation of urinary tract 
stones.17 In our study, there was no relationship 
between the use of hypertension drugs with 
the presence of urinary tract stones. This is 
likely due to the length of time hypertension 
patients have suffered from hypertension and 
the duration of taking antihypertensive drugs 
are not recorded. 
Two of the risk factors associated with 
the presence of urinary tract stones in BPH 
patients are age and diabetes mellitus. With 
the increasing age, the risk for urinary tract 
stones in BPH patients is getting higher. The 
peak age of urinary tract stones in this study 
was 60–69 years old. After the peak of its age, 
the risk of urinary tract stones will diminish.6 
Diabetes mellitus is one of the metabolic 
syndromes in addition to hypertension and 
obesity which is the risk factor of urinary tract 
stones.18 Insulin resistance caused by diabetes 
mellitus will lead to the formation of uric acid 
stones of 30–40%.18 Other studies mentioned 
that diabetics with urinary stones have 6 times 
the risk of uric acid stone formation compared 
to people with urinary tract stones that do not 
have diabetes mellitus.19 The results of our 
study reveals that BPH patients accompanied 
by diabetes mellitus have a 3-fold risk of 
urinary tract stones compared to BPH patients 
without diabetes mellitus. 
This study has some limitations. The 
source of this study was secondary data from 
the registries and medical records with many 
missing data in the medical records, resulting 
in incomplete analysis of each variable used a 
different number of samples. The method used 
in this study is a retrospective design. The 
development of the disease could thus not be 
followed up and monitored.  Moreover, urinary 
tract stones are formed due to many factors, 
both intrinsic and extrinsic. In this study, not 
all factors have been examined.
To conclude, diabetes mellitus is associated 
with the occurrence of urinary tract stones in 
BPH patients. The diabetes mellitus status can 
be used as information for conducting imaging 
tests routinely to identify urinary tract stones 
in BPH patients.
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